President Calls for Review of Allowing Mifegyne
Attention Focused on Amendments to the Mother and Child Health Act

President Lee Jaemyung has publicly called for a review of allowing the use of Mifegyne, an abortion drug currently unapproved in South Korea, even before changes to the law are made. This move is expected to rekindle efforts to address the legislative vacuum regarding abortion in the country. Since the Constitutional Court’s ruling of unconstitutionality on the existing criminal code regarding abortion on April 11, 2019, the National Assembly has failed to pass follow-up legislation for seven years. President Lee's proposal offers an alternative. As a result, there is renewed interest in whether several amendments to the Mother and Child Health Act, which are currently pending in the National Assembly, will move forward.


During a Cabinet meeting at the Blue House on July 14, President Lee stated regarding Mifegyne, “Since the discussion on the permissible scope of abortion has not concluded, Mifegyne remains unapproved. As a result, women in need are resorting to purchasing it overseas, which has led to accidents. I do not believe it is right to allow this situation to continue.”


In response, Minister of Gender Equality and Family Won Minkyoung replied, “Even before revising the Mother and Child Health Act, it would be possible for the Ministry of Food and Drug Safety to allow its use.” President Lee added, “Even before the legislation, perhaps physicians could be allowed to make discretionary decisions. It does not seem legally impossible.”


On July 15, Minister Won again told reporters, “In many countries, the use of such drugs is permitted under existing guidelines or product labels, even in the absence of legislation. Relevant agencies in Korea, including the Ministry of Food and Drug Safety, should also actively review ways to introduce the medication.”


Mifegyne is an oral medication for medical abortion that can be used in early pregnancy. It works by cutting off the nutrient supply to an embryo implanted in the uterus, detaching it from the uterine lining, and then contracting the uterus to expel the detached embryo. The drug is approved for use in over 100 countries, including France.


The U.S. Food and Drug Administration (FDA) currently authorizes the prescription of Mifegyne for pregnant women within 10 weeks of gestation. When first approved in 2000, its use was limited to pregnancies within seven weeks, but the scope was expanded in 2016.


Previously, the Constitutional Court ruled that Article 269(1) of the Criminal Code, which punishes women for self-induced abortion, and Article 270(1), which punishes physicians who perform abortions with the pregnant woman’s request or consent, excessively restrict a pregnant woman’s right to self-determination.


The Constitutional Court also provided a temporal guideline for abortion, stating that a woman has sufficient time to decide whether to give birth before the fetus becomes viable—usually around 22 weeks of pregnancy when it could survive outside the womb.


However, the Court recognized that an immediate ruling of unconstitutionality could lead to a legal void, eliminating all regulations on abortion during the entirety of pregnancy. Therefore, it required the National Assembly to revise the relevant laws by December 31, 2020.


Despite this, all proposed amendments to the Criminal Code and the Mother and Child Health Act—submitted separately by the government and ruling and opposition parties during the 21st National Assembly—were discarded at the end of the Assembly’s term. As a result, the previous criminal provisions on abortion lost effect as of January 1, 2021, but, with no follow-up legislation, the legal vacuum continues.


Prosecutors are currently applying temporary criteria in handling these cases. If the abortion took place within 12 weeks of pregnancy and there are clear social or economic grounds, they seek a suspended sentence. In cases of abortion within 22 weeks of pregnancy, prosecution is deferred until the National Assembly enacts new legislation. The 12-week benchmark is based on practices in some countries, such as the United States and parts of Europe, where abortions are permitted within 12 weeks regardless of the reason.


Currently, several amendments to the Mother and Child Health Act, aimed at establishing a system for abortion services, are pending in the National Assembly. One amendment—sponsored by Assemblywoman Son Sol of the Progressive Party—proposes changing the legal term from “artificial termination of pregnancy” to “induced abortion” and permitting the use of abortion-inducing drugs in addition to surgery. Amendments sponsored by Assemblywomen Nam Insoon and Lee Sujin of the Democratic Party of Korea also include provisions to allow the use of abortion medications.



Kim Jihyun, Law Times Reporter


※This article is based on content supplied by Law Times.

This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing